IP Library › Patent Application 18866089
Patent Application
App. No. 18/866,089

USE OF CYTOPROTECTANT FORMULATIONS IN CELL OR TISSUE TRANSPORT AND/OR STORAGE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/866,089
Abstract

A method for storing or transporting cells, tissues or organs including: preparing a cytoprotectant formulation by mixing a first precursor solution including a balanced salt solution having a pH of from 7.6 to about 8.0 and a second precursor solution comprising water, D-glucose, glutathione, ascorbic acid, and optionally L-arginine at a pH of about 3-5; extracting cells, tissues or organs during a biopsy procedure; and storing or transporting the cells, tissues or organs in the cytoprotectant formulation. The cytoprotectant formulation can also be prepared by reconstituting a powder formulation in a saline or sterile water media to form a cytoprotectant formulation, where the powder formulation includes a reducing agent, an antioxidant, a sugar, a buffering agent, physiologically acceptable salts, optionally a nitric oxide substrate, and is reconstituted at a point of use in a saline or sterile water media.

Claims (9)

1 . A method for storing or transporting cells, tissues or organs, comprising:

reconstituting a powder formulation in a saline or sterile water media to form a cytoprotectant formulation;

extracting the cells, tissues or organs during a biopsy procedure; and

bringing the cells, tissues or organs into contact with the cytoprotectant formulation, and

storing the cells, tissues or organs in the cytoprotectant formulation,

wherein the powder formulation comprises a reducing agent; an antioxidant; a sugar;

optionally a nitric oxide substrate; a buffering agent; and a physiologically acceptable salt, and

wherein the powder formulation when reconstituted at a point of use in a saline or sterile water media forms a reconstituted formulation having a pH of about 7.

2 - 23 . (canceled)

Assignments (2)
SECURITY INTEREST Recorded Aug 22, 2025
From: MARIZYME, INC.
To: QUALIGEN THERAPEUTICS, INC.
Reel/Frame 072517/0509 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2024
From: PACHUK, CATHY; CHANDRAN, SATISH
To: MARIZYME, INC.
Reel/Frame 069299/0095 →